All stock lists
Amylyx Pharmaceuticals, Inc. (AMLX)
NASDAQ: AMLX · Real-Time Price · USD
Healthcare · Drug Manufacturers - Specialty & Generic
26.79-0.41 (-1.51%)
Insider Score
––Not scored
AMLX Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
AMLX Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Revenue Growth (YoY) | — | — | — | — | — | — |
| Cost of Revenue | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A Expense | 21.93 M | 16.17 M | 15.39 M | 16.17 M | 15.64 M | — |
| R&D Expense | 23.77 M | 27.61 M | 21.21 M | 19.86 M | 27.22 M | — |
| Operating Expenses | 45.69 M | 43.78 M | 36.60 M | 36.03 M | 42.86 M | — |
| Operating Income | -45.69 M | -43.78 M | -36.60 M | -36.03 M | -42.86 M | — |
| Pretax Income | -43.42 M | -41.28 M | -32.95 M | -34.39 M | -41.44 M | — |
| Tax Provision | — | — | 46.00 K | 0.00 | 0.00 | 0.00 |
| Net Income | -43.42 M | -41.28 M | -33.00 M | -34.39 M | -41.44 M | — |
| EPS (Basic) | -0.39 | -0.37 | -0.30 | -0.37 | -0.46 | — |
| EPS (Diluted) | -0.39 | -0.37 | -0.30 | -0.37 | -0.46 | — |
| Shares Outstanding | 111.20 M | 110.56 M | 109.84 M | 93.33 M | 89.14 M | — |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.